Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo.

Zhang X, Wang X, Song X, Liu C, Shi Y, Wang Y, Afonja O, Ma C, Chen YH, Zhang L.

Cancer Sci. 2010 Oct;101(10):2163-70. doi: 10.1111/j.1349-7006.2010.01664.x. Epub 2010 Aug 24.

2.

PDCD4 inhibits the malignant phenotype of ovarian cancer cells.

Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL, Wang Q, Gao Q, Ma CH, Sun WS, Fu QZ, Chen YH, Zhang LN.

Cancer Sci. 2009 Aug;100(8):1408-13. doi: 10.1111/j.1349-7006.2009.01210.x. Epub 2009 Jun 1.

3.

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.

Mol Med. 2011;17(11-12):1262-74. doi: 10.2119/molmed.2011.00176. Epub 2011 Aug 19.

4.

Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.

Wang W, Zhao J, Wang H, Sun Y, Peng Z, Zhou G, Fan L, Wang X, Yang S, Wang R, Fang D.

Exp Cell Res. 2010 Sep 10;316(15):2456-64. doi: 10.1016/j.yexcr.2010.05.027. Epub 2010 Jun 2.

PMID:
20595005
5.

Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.

Dodier P, Piché A.

Gynecol Oncol. 2006 Feb;100(2):254-63. Epub 2005 Sep 26.

PMID:
16188300
6.

Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.

Yang YI, Kim JH, Lee KT, Choi JH.

Gynecol Oncol. 2011 Dec;123(3):588-96. doi: 10.1016/j.ygyno.2011.08.031. Epub 2011 Sep 25.

PMID:
21945308
7.
8.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

PMID:
21885917
9.
10.

[Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].

Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW.

Ai Zheng. 2006 Apr;25(4):398-403. Chinese.

PMID:
16613669
11.

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.

Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.

Cancer Res. 1996 Feb 1;56(3):556-62.

12.

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.

Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 Apr;105(1):31-44. Epub 2007 Feb 1.

PMID:
17275076
13.

Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo.

Chang HL, Su JH, Yeh YT, Lee YC, Chen HM, Wu YC, Yuan SS.

Cancer Lett. 2008 Aug 18;267(1):85-95. doi: 10.1016/j.canlet.2008.03.007. Epub 2008 Apr 21.

PMID:
18430509
14.

Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.

Xiang J, Gómez-Navarro J, Arafat W, Liu B, Barker SD, Alvarez RD, Siegal GP, Curiel DT.

J Gene Med. 2000 Mar-Apr;2(2):97-106.

PMID:
10809143
15.

Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.

Henkels KM, Turchi JJ.

Cancer Res. 1999 Jul 1;59(13):3077-83. Erratum in: Cancer Res 2000 Feb 15;60(4):1150.

16.

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.

Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D.

Mol Cancer Ther. 2007 Feb;6(2):762-72.

17.

[Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line].

Yang XK, Zheng F, Chen JH, Gao QL, Lu YP, Wang SX, Wang CY, Ma D.

Ai Zheng. 2002 Dec;21(12):1288-91. Chinese.

PMID:
12520732
18.

Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.

Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K.

Gynecol Oncol. 2003 Apr;89(1):37-47.

PMID:
12694652
19.

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.

Gynecol Oncol. 2001 Jun;81(3):380-90.

PMID:
11371126

Supplemental Content

Support Center